Latest Conference Articles

New findings at Elevate Derm highlight remibrutinib's rapid and sustained efficacy in reducing chronic spontaneous urticaria symptoms, offering hope for patients.

Psoriasis in high impact areas responded well to icotrokinra, presenting a potential exciting option for patients.

At the DERM 2025 conference, Scott Boswell, MD, shares tips for combining therapies.

James Song, MD, discussed his UnlIMMited DERM 2025 poster detailing risankizumab's efficacy for genital and scalp psoriasis.

Join Dermatology Times at the 2025 Elevate-Derm Summer Conference for expert insights and live updates from Park City, Utah.

Joe Gorelick, MSN, FNP-C, discusses upcoming highlights and new data expected at the upcoming DERM 2025 CME Conference.

We want to know: Will you be attending the conference in Seattle this week?

The 2025 Fall Clinical Dermatology Conference energized PAs and NPs with innovative strategies, addressing burnout, digital branding, and personalized medicine.

Anabela Cardoso, MD, reflects on specific data from the phase 3b ADmirable trial evaluating the safety and efficacy of lebrikizumab in patients with moderate to severe AD and pigmented skin.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of July.

Unlock exclusive insights from SDPA 2025 and get expert pearls, emerging data, and clinical strategies at your fingertips. Share with us to access the full recap.

Catch up on coverage from the fourth and final day of the 2025 SDPA Annual Summer Dermatology Conference held in Washington, DC.

Expert our review of the top pearls, clinical strategies, and practice-changing tips from leading voices in dermatology at SDPA’s 2025 Summer Conference.

Test your knowledge of key words, terms, and pearls associated with this weekend's SDPA Annual Summer Dermatology Conference.

From JAK inhibitors to trichoscopy and contact allergy clues, experts at SDPA 2025 shared their top clinical pearls for managing alopecia and hair loss.

A poster from SDPA 2025 showed brodalumab maintains a consistent safety profile with no completed suicides and low infection rates.

Eileen Cheever, MPAS, PA-C, highlights the growing role of JAK inhibitors in dermatology, including emerging data on prurigo nodularis and adolescent alopecia areata.

Maria Hordinsky, MD, urges dermatology clinicians to consider allergic contact dermatitis when scarring alopecia treatments fail.

Catch up on coverage from the third day of the 2025 SDPA Annual Summer Dermatology Conference held in Washington, DC.

At SDPA 2025, a poster evaluating the STRATUM trial showed roflumilast foam 0.3% effectively treats seborrheic dermatitis with minimal pigment changes.

David Cotter, MD, PhD, discusses diagnosing alopecia areata and selecting systemic treatments, including JAK inhibitors, from his SDPA 2025 presentation.

Amy Spizuoco, DO, FAOCD, shared how trichoscopy enhances alopecia evaluation by improving diagnostic speed, accuracy, and reducing biopsy need.

Nearly all injection site reactions among patients in the ARCADIA 1/2 and OLYMPIA 1/2 clinical trials were mild and transient in nature.

Ongoing maintenance therapy is essential to avoid relapse and preserve gains in repigmentation for patients with vitiligo, according to Gina Mangin, MPAS, PA-C.

Orit Markowitz, MD, shares how a color-focused strategy helps spot early malignancies—even 2-mm lesions—across all skin tones.

A yearlong study showed dupilumab alone effectively prevented flares in moderate to severe atopic dermatitis, with consistent safety across various dosing schedules.

Catch up on coverage from the second day of the 2025 SDPA Annual Summer Dermatology Conference held in Washington, DC.